KB-0742 is under clinical development by Kronos Bio and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KB-0742’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KB-0742 is under development for the treatment of castration resistant prostate cancer, soft tissue sarcoma and MYC-dependent acute myeloid leukemia, solid tumors, ovarian cancer, chordoma, non-Hodgkin lymphoma, soft tissue sarcoma, non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), triple-negative breast cancer (TNBC), gastric cancer, gastroesophageal (GE) junction carcinomas, diffuse large B-cell carcinoma, NUT midline carcinoma, adenoid cystic carcinoma, neuroblastoma tumors, ewing sarcoma (EW) and alveolar rhabdomyosarcoma (ARMS). It is administered through oral route as a capsule. The drug candidate acts by targeting cyclin-dependent kinase 9 (CDK9). It is developed based on small molecule microarray (SMM) platform.
Kronos Bio overview
Kronos Bio (Kronos) is a biopharmaceutical company that discovers, develops and markets drugs for treatment of cancer. The company’s lead product candidate, an entospletinib spleen tyrosine kinase inhibitor is being developed for the treatment of NPM1-mutated acute myeloid leukemia (AML). It is investigating KB-0742, a cyclin dependent kinase 9 inhibitor indicated for the treatment of MYC-amplified solid tumors. Kronos is also evaluating drugs targeting prostate cancer, multiple myeloma, neuroendocrine cancer and acute myeloid leukemia. The company operates a research facility in Cambridge, Massachusetts. Kronos is headquartered in San Mateo, California, the United States.
For a complete picture of KB-0742’s drug-specific PTSR and LoA scores, buy the report here.